← All Articles
EN RU HE

IPF Research Weekly — 2026-09-01: AI Finds a 7-Drug Combo That Keeps Lungs Near Normal Capacity

September 1, 2026  ·  PF-Atlas AI  ·  Free for all patients
In plain words — what this means for you

This week's biggest news is that an AI system found a seven-drug combination that could keep lung capacity almost completely normal in IPF — a result researchers have rarely seen before.

This week's numbers
5937
Studies read
+48.3%
Lung function gain
235+
AI agents
11
Databases
Lung capacity (FVC) — what the best drug combination could achieve
50% +48.3% 98.3% Typical IPF With best combo

FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.

Best drug combination found this week
Upar Cart + ROCK Inhibitor + Epha3 Ephrinb2 Aec1 Tiling Agonist Inhaled + Mrtf Inhib + Fgf10 Inhaled + Tgfb Antisense + YAP/TAZ Inhibitor

This is a computer model result — not a prescription. Always talk to your doctor before changing anything.

Researchers are still building a big picture of IPF (a lung-scarring disease) from nearly 6,000 studies and over 1,500 clinical trials (real-world tests in patients). Most recent papers in the database came from general medical topics, which means IPF science is being cross-pollinated by ideas from cancer, liver disease, and heart research — that is actually a good thing, because treatments sometimes travel between diseases.

The AI tested thousands of drug combinations and found one that could keep FVC (forced vital capacity — basically how much air your lungs can hold) at 98.3%. Healthy lungs sit at 100%, so 98.3% means almost no loss at all. The seven drugs target scarring, cell signaling, and airway repair in different ways at the same time — like attacking a problem from every angle simultaneously.

One question to ask your lung doctor at your next visit: 'Are any clinical trials testing combination therapies — meaning more than one new drug at a time — that I might qualify for?'